Betahistine — NZ Medication Guide

📋 Reviewed by a Registered Pharmacist NZ — This information is for general educational purposes only and does not replace professional medical advice. Always consult your doctor or pharmacist before starting, stopping, or changing any medication.

What is Betahistine?

Betahistine is a histamine analogue used for the treatment of Ménière’s disease and vestibular disorders causing vertigo. This medication is funded by Pharmac for Ménière’s disease.

What is Betahistine Used For?

Betahistine is used for Ménière’s disease — a disorder of the inner ear causing recurring episodes of vertigo, tinnitus (ringing in the ears), fluctuating hearing loss, and ear fullness. It reduces the frequency and severity of vertigo attacks.

How Does Betahistine Work?

Betahistine acts as a weak H1 histamine receptor agonist and a potent H3 receptor antagonist in the inner ear vasculature. H3 antagonism promotes histamine release, which causes vasodilation in the stria vascularis of the cochlea — improving blood flow and reducing endolymphatic hydrops (the fluid excess thought to cause Ménière’s symptoms).

How to Take Betahistine

16–24 mg three times daily with food. Standard maintenance: 48 mg/day in divided doses. Some patients require up to 48 mg three times daily for adequate symptom control. Results may take several weeks or months to become apparent.

Common Side Effects of Betahistine

• Nausea and indigestion
• Headache
• Abdominal discomfort

Serious Side Effects — Seek Medical Attention

Contact your doctor or call 111 immediately if you experience any of the following:

• Bronchospasm (use with caution in asthma — betahistine may exacerbate bronchospasm in susceptible patients)
• Severe hypersensitivity reactions (urticaria, angioedema — rare)
• Peptic ulcer exacerbation (rare — caution in peptic ulcer disease)

Drug Interactions

Betahistine may interact with other medicines. Always inform your doctor and pharmacist of all medications you are taking. Key interactions include:

• Antihistamines (may reduce betahistine efficacy via H1 receptor competition)
• MAOIs (avoid — may inhibit betahistine metabolism)

New Zealand Prescribing Information

Betahistine dihydrochloride (8 mg and 16 mg tablets — Serc® and generics) is funded by Pharmac for Ménière’s disease. Evidence for betahistine’s efficacy is debated — some large trials (BEMED trial) failed to show superiority over placebo, while clinical experience suggests benefit in many patients. Its favourable tolerability profile supports its continued use in practice pending further evidence.

Frequently Asked Questions

Is there good evidence betahistine works for Ménière’s disease?

Evidence is mixed — some smaller trials and clinical experience suggest benefit, while the large BEMED trial (2016) did not show superiority over placebo. Many guidelines still recommend betahistine as a first-line option given its good tolerability and some patients’ clear clinical response. Discuss with your ENT specialist if benefit is uncertain after a trial period.

How long before betahistine helps my symptoms?

It may take several weeks to months of regular treatment before improvement is noticeable. Consistent daily dosing is important — betahistine is not a quick-relief medicine.

References & Further Information

The following New Zealand and international resources were used to inform this page. We encourage you to consult these authoritative sources for the most current information:

• New Zealand Formulary — Betahistine
• Pharmac Funded Medicines Schedule
• BPAC NZ — Vertigo and Dizziness

⚠️ Disclaimer: This page is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or a qualified health provider. In New Zealand, medication availability and funding may vary — check with Pharmac or your pharmacist for current information.

Reviewed by a Registered Pharmacist NZ